Johnson & Johnson

Registry data published in Neurosurgery suggests Codman’s Enterprise stent-assisted coil embolization system is an effective tool in the occlusion of neurovascular aneurysms with positive outcomes at 21 months.

Sandra E. Peterson will join Johnson & Johnson (NYSE: JNJ) on December 1, 2012, as Group Worldwide Chairman and member of the Company’s Executive Committee. She will have responsibility for the Consumer Group of Companies, Information Technology, and Global Supply Chain.

So who dropped the ball? It looks like one of Synthes Hemostatic Bone Putty’s constituents is flammable, which makes it look like the culprit in the flammable bone putty debacle.

J&J subsidiary business Ethicon Endosurgery has issued a voluntary recall of certain lots of its PROXIMATE® PPH Hemorrhoidal Circular Stapler and Accessories. The recall was provoked by reports of difficulty firing the device although the company seems to have no problem doing so when reloading returned devices.

Ethicon Endo-Surgery, Inc. has announced U.S. FDA 510(k) clearance of its HARMONIC ACE®+ Shears with Adaptive Tissue Technology. The company says this represents the next generation in its “best-in-class” HARMONIC® portfolio of ultrasonic surgical devices that can handle multiple surgical jobs.

Codman has announced receipt of U.S FDA approval through a PMA supplement for its MEDSTREAM™ Programmable Infusion System. MEDSTREAM is an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

Codman Neurovascular, Inc., has announced the launch of the DELTAMAXX™ Microcoil System, ORBIT GALAXY® G2 Microcoils, and ENVOY DA Guiding Catheter at this year’s SNIS meeting in San Diego.

Johnson & Johnson has just announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011, albeit with a significant currency loss painting a gloomier picture than the top line figures suggest.

Ethicon has issued a dire warning about inappropriate use of its Evicel® spray applicator, which raises the question of how well important information like this gets distributed outside US.

J&J’s Cordis division is worried that one lot of its Fire Star Rx Balloon Catheters runs the risk of deflating too slowly or worse, not at all. The recall is limited to certain Far Eastern countries.

According to a news release from Reuters agency, Johnson & Johnson has, as expected, won U.S. antitrust approval to buy Swiss medical device company Synthes Inc. if it sells its system for surgically treating serious wrist fractures, and related assets (to Biomet Inc.), the Federal Trade Commission said on Monday.

Ethicon’s legal representative has written to a federal judge in West Virginia stating it intends to stop selling four vaginal mesh implants after being sued by more than 600 women who say the products caused internal injuries.

Laparoscopic surgery instruments may need to be larger than the access portal through which they are delivered, which means some degree of internal assembly could open up possibilities for more useful devices. Now the way is clear as FDA issues its first such clearance.

The First Medical Device Acquisition in China for the Johnson & Johnson Family of Companies is Guangzho Bioseal Who’s Biologic Product Complements J&J’s Existing Haemostat Portfolio.

There was an inevitability about the whole thing, but still J&J and Synthes execs must be relieved that the EU commission into their mega deal has agreed to the takeover following J&J’s concessionary divestiture of its existing trauma business. Wonder how those guys are feeling though.

What an interesting deal. J&J’s Ethicon, not known for its soft negotiating stance, has agreed a deal in which it pays Angiotech for IP relating to the company’s Quill suture technology, yet is allowing the pharma company to keep on selling it.